112 related articles for article (PubMed ID: 14769885)
1. Hepatitis B virus X antigen promotes transforming growth factor-beta1 (TGF-beta1) activity by up-regulation of TGF-beta1 and down-regulation of alpha2-macroglobulin.
Pan J; Clayton M; Feitelson MA
J Gen Virol; 2004 Feb; 85(Pt 2):275-282. PubMed ID: 14769885
[TBL] [Abstract][Full Text] [Related]
2. Activation of fibronectin gene expression by hepatitis B virus x antigen.
Norton PA; Reis HM; Prince S; Larkin J; Pan J; Liu J; Gong Q; Zhu M; Feitelson MA
J Viral Hepat; 2004 Jul; 11(4):332-41. PubMed ID: 15230856
[TBL] [Abstract][Full Text] [Related]
3. A cellular gene up-regulated by hepatitis B virus-encoded X antigen promotes hepatocellular growth and survival.
Lian Z; Liu J; Pan J; Satiroglu Tufan NL; Zhu M; Arbuthnot P; Kew M; Clayton MM; Feitelson MA
Hepatology; 2001 Jul; 34(1):146-57. PubMed ID: 11431746
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of CK2 activity by TGF-beta1 promotes IkappaB-alpha protein stabilization and apoptosis of immortalized hepatocytes.
Cavin LG; Romieu-Mourez R; Panta GR; Sun J; Factor VM; Thorgeirsson SS; Sonenshein GE; Arsura M
Hepatology; 2003 Dec; 38(6):1540-51. PubMed ID: 14647065
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B virus X protein protects against anti-Fas-mediated apoptosis in human liver cells by inducing NF-kappa B.
Pan J; Duan LX; Sun BS; Feitelson MA
J Gen Virol; 2001 Jan; 82(Pt 1):171-182. PubMed ID: 11125170
[TBL] [Abstract][Full Text] [Related]
6. The non-ankyrin C terminus of Ikappa Balpha physically interacts with p53 in vivo and dissociates in response to apoptotic stress, hypoxia, DNA damage, and transforming growth factor-beta 1-mediated growth suppression.
Chang NS
J Biol Chem; 2002 Mar; 277(12):10323-31. PubMed ID: 11799106
[TBL] [Abstract][Full Text] [Related]
7. Transient activation of NF-kappaB through a TAK1/IKK kinase pathway by TGF-beta1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation.
Arsura M; Panta GR; Bilyeu JD; Cavin LG; Sovak MA; Oliver AA; Factor V; Heuchel R; Mercurio F; Thorgeirsson SS; Sonenshein GE
Oncogene; 2003 Jan; 22(3):412-25. PubMed ID: 12545162
[TBL] [Abstract][Full Text] [Related]
8. TGF-beta1 inhibits NF-kappaB activity through induction of IkappaB-alpha expression in human salivary gland cells: a possible mechanism of growth suppression by TGF-beta1.
Azuma M; Motegi K; Aota K; Yamashita T; Yoshida H; Sato M
Exp Cell Res; 1999 Jul; 250(1):213-22. PubMed ID: 10388535
[TBL] [Abstract][Full Text] [Related]
9. Growth factor-binding sequence in human alpha2-macroglobulin targets the receptor-binding site in transforming growth factor-beta.
Arandjelovic S; Freed TA; Gonias SL
Biochemistry; 2003 May; 42(20):6121-7. PubMed ID: 12755614
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of ErbB-2 in liver is associated with hepatitis B x antigen and shorter survival in patients with liver cancer.
Liu J; Ahiekpor A; Li L; Li X; Arbuthnot P; Kew M; Feitelson MA
Int J Cancer; 2009 Oct; 125(8):1894-901. PubMed ID: 19610068
[TBL] [Abstract][Full Text] [Related]
11. The hepatitis B x antigen effector, URG7, blocks tumour necrosis factor alpha-mediated apoptosis by activation of phosphoinositol 3-kinase and beta-catenin.
Pan J; Lian Z; Wallet S; Feitelson MA
J Gen Virol; 2007 Dec; 88(Pt 12):3275-3285. PubMed ID: 18024896
[TBL] [Abstract][Full Text] [Related]
12. c-Jun N-terminal kinase inhibitor favors transforming growth factor-β to antagonize hepatitis B virus X protein-induced cell growth promotion in hepatocellular carcinoma.
Wu YH; Ai X; Liu FY; Liang HF; Zhang BX; Chen XP
Mol Med Rep; 2016 Feb; 13(2):1345-52. PubMed ID: 26648552
[TBL] [Abstract][Full Text] [Related]
13. Role of transforming growth factor-beta1-smad signal transduction pathway in patients with hepatocellular carcinoma.
Ji GZ; Wang XH; Miao L; Liu Z; Zhang P; Zhang FM; Yang JB
World J Gastroenterol; 2006 Jan; 12(4):644-8. PubMed ID: 16489684
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways.
Park JI; Lee MG; Cho K; Park BJ; Chae KS; Byun DS; Ryu BK; Park YK; Chi SG
Oncogene; 2003 Jul; 22(28):4314-32. PubMed ID: 12853969
[TBL] [Abstract][Full Text] [Related]
15. Plasma levels of transforming growth factor-1beta and alpha2-macroglobulin before and after radical prostatectomy: association to clinicopathological parameters.
Sinnreich O; Kratzsch J; Reichenbach A; Gläser C; Huse K; Birkenmeier G
Prostate; 2004 Nov; 61(3):201-8. PubMed ID: 15368477
[TBL] [Abstract][Full Text] [Related]
16. Murine alpha-macroglobulins demonstrate divergent activities as neutralizers of transforming growth factor-beta and as inducers of nitric oxide synthesis. A possible mechanism for the endotoxin insensitivity of the alpha2-macroglobulin gene knock-out mouse.
Webb DJ; Wen J; Lysiak JJ; Umans L; Van Leuven F; Gonias SL
J Biol Chem; 1996 Oct; 271(40):24982-8. PubMed ID: 8798779
[TBL] [Abstract][Full Text] [Related]
17. Acceleration of c-myc-induced hepatocarcinogenesis by Co-expression of transforming growth factor (TGF)-alpha in transgenic mice is associated with TGF-beta1 signaling disruption.
Santoni-Rugiu E; Jensen MR; Factor VM; Thorgeirsson SS
Am J Pathol; 1999 Jun; 154(6):1693-700. PubMed ID: 10362794
[TBL] [Abstract][Full Text] [Related]
18. The transforming growth factor-beta/SMAD signaling pathway is present and functional in human mesangial cells.
Poncelet AC; de Caestecker MP; Schnaper HW
Kidney Int; 1999 Oct; 56(4):1354-65. PubMed ID: 10504488
[TBL] [Abstract][Full Text] [Related]
19. NF-kappaB and activator protein 1 response elements and the role of histone modifications in IL-1beta-induced TGF-beta1 gene transcription.
Lee KY; Ito K; Hayashi R; Jazrawi EP; Barnes PJ; Adcock IM
J Immunol; 2006 Jan; 176(1):603-15. PubMed ID: 16365456
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B x antigen up-regulates vascular endothelial growth factor receptor 3 in hepatocarcinogenesis.
Lian Z; Liu J; Wu M; Wang HY; Arbuthnot P; Kew M; Feitelson MA
Hepatology; 2007 Jun; 45(6):1390-9. PubMed ID: 17539024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
